Managing integrated continuous bioprocesses in real time: Deviations in product quality

The N-mAb case study was produced by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to support teaching and learning for both industry and regulators around adoption of advanced manufacturing process technologies such as integrated continuous bioprocesses (ICB) fo...

Full description

Saved in:
Bibliographic Details
Published in:Biotechnology progress 2024-03, Vol.40 (2), p.e3414-e3414
Main Authors: Grampp, Gustavo, Bosley, Allen, Qadan, Maen, Schiel, John, Spasoff, Andy, Valax, Pascal, Schaefer, Gene
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal
Batch processing
Biological Products
Biopharmaceuticals
Case studies
Deviation
Integrated control
Manufacturing
Manufacturing industry
Monoclonal antibodies
Real time
Technology, Pharmaceutical
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The N-mAb case study was produced by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to support teaching and learning for both industry and regulators around adoption of advanced manufacturing process technologies such as integrated continuous bioprocesses (ICB) for monoclonal antibodies (mAbs). N-mAb presents the evolution of an integrated control strategy, from early clinical through process validation and commercial manufacturing with a focus on elements that are unique to ICB. The entire N-mAb case study is quite comprehensive, therefore this publication presents a summary of the chapter on managing deviations from a state of control in real time. This topic is of critical importance to ICB and is also applicable to batch processes operated at a rapid cadence.
ISSN:8756-7938
1520-6033
DOI:10.1002/btpr.3414